Actuate Therapeutics President, CEO and Director Daniel M. Schmitt Reports Acquisition of $49,999.62 in Common Shares

Bitget2026/10/29 13:36

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Actuate Therapeutics President, CEO and Director Daniel M. Schmitt purchased 140,844 common shares at $0.355 each.
His direct common stock holdings increased to 442,560 shares.
Schmitt also acquired warrants to purchase 70,422 common shares at an exercise price of $0.45 per share.
The warrants are immediately exercisable and expire October 28, 2031.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Actuate Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001683168-26-008147), on October 29, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

According to reports, the trading firm JonesTrading is marketing up to $500 million worth of stock shares on behalf of some investors, at a 3% to 5% premium over the IPO issue price. This indicates that investors are already transferring their anticipated IPO allotted shares before the IPO is officially issued.

华尔街见闻•2026/11/10 23:03